Patents by Inventor Sheau Yu Hsu
Sheau Yu Hsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11666633Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: GrantFiled: July 24, 2018Date of Patent: June 6, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Chia Lin Chang
-
Publication number: 20190183978Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: ApplicationFiled: July 24, 2018Publication date: June 20, 2019Inventors: Sheau Yu Hsu, Chia Lin Chang
-
Patent number: 10058592Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: GrantFiled: January 13, 2016Date of Patent: August 28, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Chia Lin Chang
-
Patent number: 9815881Abstract: Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.Type: GrantFiled: January 31, 2013Date of Patent: November 14, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jae-Il Park, Sheau Yu Hsu
-
Patent number: 9694051Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: GrantFiled: April 5, 2012Date of Patent: July 4, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Chia Lin Chang
-
Publication number: 20170014485Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: ApplicationFiled: January 13, 2016Publication date: January 19, 2017Inventors: Sheau Yu Hsu, Chia Lin Chang
-
Publication number: 20150307571Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: July 7, 2015Publication date: October 29, 2015Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20150025125Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: June 25, 2013Publication date: January 22, 2015Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20140155329Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: ApplicationFiled: April 5, 2012Publication date: June 5, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Chia Lin Chang
-
Patent number: 8481686Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: GrantFiled: October 1, 2010Date of Patent: July 9, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Patent number: 8389475Abstract: Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.Type: GrantFiled: August 6, 2010Date of Patent: March 5, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jae-II Park, Sheau Yu Hsu
-
Publication number: 20120157379Abstract: Novel gastric inhibitory peptide (GIP) polypeptide compositions are provided. Human GIP alleles encode an extended peptide, referred to herein as GIP55S or GIP55G, which is resistant to serum degradation, relative to the known mature GIP peptide. GIP55S or GIP55G peptides find use where it is desirable to modulate insulin secretion.Type: ApplicationFiled: July 29, 2010Publication date: June 21, 2012Inventor: Sheau Yu Hsu
-
Publication number: 20120066775Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: October 1, 2010Publication date: March 15, 2012Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20110130332Abstract: Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.Type: ApplicationFiled: August 6, 2010Publication date: June 2, 2011Inventors: Jae-II Park, Sheau Yu Hsu
-
Patent number: 7829330Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: GrantFiled: November 5, 2007Date of Patent: November 9, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Publication number: 20090298770Abstract: High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful as therapeutic agents capable of inhibiting the action of relaxin and InsL3. The receptors and fragments thereof also find use in the screening and design of relaxin agonists and antagonists. Conditions treatable with relaxin agonists or antagonists include prevention or induction of labor, treatment of endometriosis, treatment of skin conditions such as scleroderma that require collagen or extracellular matrix remodelling. Additionally, relaxin has been implicated in the dilation of blood vessels' smooth muscle cells directly and through release of nitric oxide and atrial natriuretic peptide.Type: ApplicationFiled: April 20, 2009Publication date: December 3, 2009Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Patent number: 7531313Abstract: High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful as therapeutic agents capable of inhibiting the action of relaxin and InsL3. The receptors and fragments thereof also find use in the screening and design of relaxin agonists and antagonists. Conditions treatable with relaxin agonists or antagonists include prevention or induction of labor, treatment of endometriosis, treatment of skin conditions such as scleroderma that require collagen or extracellular matrix remodelling. Additionally, relaxin has been implicated in the dilation of blood vessels' smooth muscle cells directly and through release of nitric oxide and atrial natriuretic peptide.Type: GrantFiled: August 1, 2006Date of Patent: May 12, 2009Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Publication number: 20080145927Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: November 5, 2007Publication date: June 19, 2008Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Patent number: 7291341Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: GrantFiled: October 8, 2003Date of Patent: November 6, 2007Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Publication number: 20040253629Abstract: Nucleic acid compositions encoding a pro-apoptotic protein, Bok (Bcl-2-related ovarian killer) are identified. Bok has conserved Bcl-2 homology domains 1, 2 and 3 and a C-terminal transmembrane region present in other Bcl-2 related proteins, but lacks the BH4 domain found only in anti-apoptotic Bcl-2 proteins. Over-expression of Bok induces apoptosis. Cell killing induced by Bok is suppressed by co-expression with selective anti-apoptotic Bcl-2 proteins. Bok is highly expressed in the ovary, testis and uterus, particularly in granulosa cells, the cell type that undergoes apoptosis during follicle atresia. Identification of Bok as a new pro-apoptotic protein with wide tissue distribution and hetero-dimerization properties facilitates elucidation of apoptosis mechanisms in reproductive and other tissues, and provides a means for manipulating apoptosis.Type: ApplicationFiled: June 16, 2004Publication date: December 16, 2004Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Aaron J.W. Hsueh, Sheau Yu Hsu